title: Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.
abstract: The antitumoral and immunostimulating properties of rViscumin (recombinant mistletoe lectin) were investigated in two mouse tumor models. After intravenous inoculation with RAW-117-P or L-1 sarcoma cells in Balb/c mice, rViscumin was given s.c. at non-toxic doses ranging from 0.3 to 150 ng rViscumin/kg. One set of experiments was performed to investigate the survival of rViscumin-treated animals. Another set was carried out to analyze the effect of rViscumin treatment on the number of tumor colonies in infiltrated lungs (RAW-117P) or liver (L-1) and the activation of immune cell subsets, respectively. An overall prolonged survival time after treatment with rViscumin and a reduction in the number of tumor colonies after administration of certain rViscumin doses was observed. Immunophenotyping of the peripheral leukocytes of treated mice revealed increased numbers of T-lymphocytes, pan-NK cells and activated monocytes. The results indicate that rViscumin has antineoplastic properties and might therefore be a promising candidate in cancer therapy.
authors.affiliation: MEMOREC Stoffel GmbH, Köln, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Schaffrath
authors.forename: U
authors.initials: U
authors.lastname: Mengs
authors.forename: T
authors.initials: T
authors.lastname: Schwarz
authors.forename: R D
authors.initials: RD
authors.lastname: Hilgers
authors.forename: J
authors.initials: J
authors.lastname: Beuth
authors.forename: B
authors.initials: B
authors.lastname: Möckel
authors.forename: H
authors.initials: H
authors.lastname: Lentzen
authors.forename: B
authors.initials: B
authors.lastname: Gerstmayer
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D007121:Immunocompetence; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy / Q000276:immunology / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000556:secondary; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D028321:Plant Preparations; D010940:Plant Proteins; D011994:Recombinant Proteins / Q000494:pharmacology; D054790:Ribosome Inactivating Proteins, Type 2; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D014118:Toxins, Biological / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D028321:Plant Preparations; D010940:Plant Proteins; D011994:Recombinant Proteins; D054790:Ribosome Inactivating Proteins, Type 2; D014118:Toxins, Biological; C009674:ribosome inactivating protein, Viscum